<DOC>
	<DOCNO>NCT02747043</DOCNO>
	<brief_summary>This trial design determine effect human body investigational medicine , ABP 798 , effect body investigational medicine give , comparable see licensed medicine , rituximab , patient CD 20 positive B-cell non Hodgkin lymphoma . This study assess investigational medicine safe effective treat CD 20 positive B-cell non Hodgkin lymphoma .</brief_summary>
	<brief_title>Study Assess ABP798 Safe &amp; Effective Treating Non Hodgkin Lymphoma Compared Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Males female ≥ 18 &lt; 80 year age Histological confirm ( lymph node extranodal region biopsy ) , Grade 1 , 2 , 3a follicular Bcell NHL express CD20 within 12 month randomization Stage 2 , 3 , 4 ( per Cotswold 's Modification Ann Arbor Staging System ) measurable disease ( per International Working Group ) subject must baseline scan ( computed tomography [ CT ] ) neck ( palpable lymph node &gt; 1.0 cm ) , chest , abdomen , pelvis assess disease burden within 28 day randomization subject must baseline bone marrow biopsy within 12 month randomization . Previously confirm positive bone marrow involvement need repeat purpose screen . Low tumor burden base Groupe d'Etudes de Lymphomes Folliculaires ( GELF ) criteria large nodal extranodal mass ≤ 7 cm 3 nodal site diameter &gt; 3 cm spleen enlargement CT assessment significant pleural peritoneal serous effusion CT normal lactate dehydrogenase ( LDH ) B symptom ( night sweat , fever [ temperature &gt; 38°C ] , weight loss &gt; 10 % previous 6 month ) Diffuse large cell component and/or Grade 3b follicular NHL History know presence central nervous system metastase Palliative radiotherapy within 3 month randomization Malignancy NHL within 5 year ( except treat insitu cervical cancer , squamous basal cell carcinoma skin ) Recent infection require course systemic antiinfective agent complete ≤ 7 day randomization ( exception uncomplicated urinary tract infection ) Subject currently enrol yet complete least 30 day 5 halflives ( whichever longer ) since end investigational device drug study ( ) , include vaccine , subject receive investigational agent ( ) Previous use either commercially available investigational chemotherapy , biological , immunological therapy NHL ( include rituximab biosimilar rituximab , antiCD20 treatment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>